Cargando…
Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
SIMPLE SUMMARY: Prostate cancer is the most frequently diagnosed non-cutaneous tumor in men in the Western world. Therapy for non-organ confined prostate cancer includes anti-androgens such as bicalutamide, enzalutamide and darolutamide. The androgen receptor is expressed during tumor initiation and...
Autor principal: | Culig, Zoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231240/ https://www.ncbi.nlm.nih.gov/pubmed/34204596 http://dx.doi.org/10.3390/cancers13122944 |
Ejemplares similares
-
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015) -
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019) -
Androgen receptor agonist and antagonist reduce response of cytokine‐induced killer cells on prostate cancer cells
por: Pungsrinont, Thanakorn, et al.
Publicado: (2023) -
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
por: Chen, Yanhua, et al.
Publicado: (2022) -
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
por: Kokal, Miriam, et al.
Publicado: (2020)